The application matrix for tylvalosin tartrate as a veterinary API divides into seven downstream processing routes, each defined by a different set of stability limits, particle-size constraints, and pharmacopoeial controls. Tylvalosin is a semisynthetic 16-membered macrolide lactone with a 3-acetyl-4-isovaleryl substitution on the tylosin backbone; the tartrate salt is used to increase water solubility, but the lactone ring remains sensitive to acid-catalyzed hydrolysis below pH 4.0 and to alkaline degradation above pH 8.0. Solid dosage forms therefore require residual moisture control, while liquid forms require buffering and antioxidant strategies. The routes below cover tablet cores, sterile parenteral solutions, hard-gelatin capsules, medicated feed premix, water-soluble granules, oral solutions, and top-dressing powders. Each section specifies the formulation ratio, equipment class, and terminal product type relevant to that route rather than repeating generic manufacturing language.

Dry granulation is the preferred solid route for oral veterinary tablets containing tylvalosin tartrate when the API fraction in the tablet core is below 10% w/w. The API is first passed through a comil fitted with a 0.5 mm square-edged screen and pre-blended with lactose monohydrate and microcrystalline cellulose at an API-to-filler ratio of 1:4 in a 100 L bin blender operated at 12 rpm for 15 min. A roller compactor with a 1.0 mm screen and a 0.8 mm milling screen produces granules with a target bulk density between 0.45 g/mL and 0.55 g/mL; this step is used because direct compression of low-dose macrolide APIs frequently produces unacceptable content uniformity. The granulated material is blended with crospovidone at 2–4% w/w and magnesium stearate at 0.5–1.0% w/w before compression on a 16-station rotary tablet press at a main compression force of 8–18 kN to a target hardness of 60–100 N. Tablet cores are evaluated against Ph. Eur. 2.9.40 for uniformity of dosage units and Ph. Eur. 2.9.1 for disintegration, with disintegration specified as not more than 15 min in water at 37 °C. The terminal product is a film-coated oral tablet for individual-animal therapy in swine respiratory disease caused by Mycoplasma hyopneumoniae; the film coat is applied with a pan coater at an inlet air temperature of 60–70 °C and a bed temperature of 38–42 °C, with a weight gain limited to 3% to avoid delayed disintegration in animals with reduced water intake. Published data for this specific API at high tablet drug load is limited; pilot-scale batches should therefore map granule moisture against Ph. Eur. 2.2.32 before full validation.

What Filtration and pH Boundaries Govern Sterile Tylvalosin Tartrate Injection Lines?

Injectable tylvalosin tartrate is processed as an aseptic solution rather than a terminally sterilized product because the 16-membered macrolide ring degrades at moist-heat sterilization conditions of 121 °C for 15 min. The formulation vehicle is prepared with Water for Injections, a phosphate or citrate buffer at 50 mM, and tonicity adjustment with sodium chloride to 280–320 mOsm/kg. The pH is adjusted to 5.5–6.5 before sterile filtration; below pH 4.0 acid-catalyzed cleavage of the neutral sugar moieties accelerates, and above pH 8.0 lactone ring opening and amine oxidation produce yellow to amber degradation products. The solution is sparged with nitrogen during compounding and filtered through a 0.22 µm polyethersulfone membrane filter under aseptic conditions. For multi-dose vials, benzyl alcohol at 1.5% v/v may be included if compatibility is confirmed; antioxidant systems based on sodium metabisulfite at 0.1% w/v are evaluated only when the vial headspace is nitrogen-flushed. The terminal product is a sterile injectable solution at 50 mg/mL or 100 mg/mL tylvalosin activity in Type I glass vials of 50 mL or 100 mL. Sterility is confirmed according to Ph. Eur. 2.6.1, bacterial endotoxins according to Ph. Eur. 2.6.14, and subvisible particulate matter according to Ph. Eur. 2.9.19. Aseptic processing follows EudraLex Volume 4 Annex 1; published stability data for the exact 100 mg/mL configuration is limited, so forced degradation studies covering pH 3.5–8.5 and oxygen headspace should precede process validation.

Hard-gelatin capsule filling is specified only where individual oral dosing is required and a tablet or oral solution is not appropriate for the target animal group. The capsule formulation uses a pre-blend of tylvalosin tartrate, lactose monohydrate, crospovidone, and magnesium stearate in a 600 L V-blender with an intensifier bar. The API is milled to a D90 below 150 µm to prevent segregation within the hopper of a dosator-type capsule filler. Tapped density is maintained between 0.45 g/mL and 0.60 g/mL, and flow is adjusted with 0.5% w/w colloidal silicon dioxide if the Carr index exceeds 25. Size 3 or 4 hard-gelatin capsules are filled with a target weight variation meeting Ph. Eur. 2.9.5; disintegration is checked by Ph. Eur. 2.9.1 with a limit of 15 min. The terminal product is an oral capsule for single-animal administration in swine breeding units where feed or water medication cannot reliably deliver the prescribed dose to an individual animal with porcine proliferative enteropathy caused by Lawsonia intracellularis. Regulatory status for this capsule format must be confirmed for the target species and country because tylvalosin capsule formulations are not the primary approved route in all jurisdictions.

Medicated Feed Premix Blend Uniformity and Carrier Selection

Feed premix manufacturing for tylvalosin tartrate requires carrier-particle engineering because the API is commonly present at 42.5 mg/g or 200 g/kg as tylvalosin activity, and segregation in a finished feed can produce either subtherapeutic or excessive intake. A 1,000 L ribbon mixer with a fill volume of 65% and a speed of 20 rpm is used after the API is pre-dispersed over a corn cob meal carrier with a particle size distribution of 300–850 µm. The carrier is dried to a moisture content below 10% w/w, and the API is bound by mixing with 1–2% w/w vegetable oil to reduce dust and electrostatic adhesion. Blend uniformity is verified by sampling at least 10 points across the mixer using HPLC with UV detection at 280 nm; the target is a relative standard deviation below 5%. In-process control follows 21 CFR 211.110, and carryover into the next batch is managed by flushing the mixer with 1–2 kg of ground maize per tonne of finished feed. The terminal product is a medicated premix for incorporation into complete swine feed for group metaphylaxis of ileitis and swine dysentery; the final inclusion rate is calculated from the approved dose and daily dry matter intake rather than fixed across jurisdictions. Segregation risk is highest when the finished feed is pneumatically conveyed over long distances after mixing; published data for this specific configuration indicates that gain-in-weight screw feeders, not gravimetric blenders alone, produce more consistent metering of low-inclusion premix into final feed.

When Tylvalosin Tartrate Is Delivered Through Proportioner-Medicated Drinking Water

Water-soluble granules are the preferred format when rapid herd-level treatment is required for swine and poultry respiratory disease, because drinking-water administration avoids the feed refusal and lag time associated with medicated feed. The granules are produced by fluid-bed granulation of tylvalosin tartrate with lactose monohydrate and povidone K30 in a top-spray granulator with an inlet air temperature of 60–65 °C and a product temperature held below 40 °C. The final granules contain 625 mg/g tylvalosin activity as tartrate and are packaged in moisture-barrier sachets. For administration, a stock solution is prepared at 25–50 g/L tylvalosin activity in water at pH 6.0–7.0; the stock solution is then metered through a proportioner set at 1% to deliver 250–500 mg/L in the drinking line. Water hardness above 300 mg/L calcium carbonate can reduce dissolution clarity, and pH above 7.8 can produce visible turbidity within 6 h. The terminal product is used for Mycoplasma gallisepticum, Mycoplasma synoviae, and Ornithobacterium rhinotracheale infections in poultry and for Mycoplasma hyopneumoniae in pigs. Unused stock solution should not be stored beyond 24 h at ambient temperature because the absence of preservative allows microbial growth and pH drift. The granule dissolution rate is measured by Ph. Eur. 2.9.1 dispersion testing as a surrogate control, with complete dispersion required within 5 min in water at 15 °C.

Oral Solution Stability Depends on Buffer Molarity, Not Solely on Final pH

Oral solution compounding for tylvalosin tartrate is governed by buffer capacity because the pH of drinking water can drift during storage, especially in polyethylene tanks under high ambient temperature. The formula is prepared from water-soluble powder or bulk API with a citrate buffer at 50 mM, adjusted to pH 5.5–6.5, and preserved with sodium methyl parahydroxybenzoate at 0.1% w/v and sodium propyl parahydroxybenzoate at 0.02% w/v when the solution is not consumed within 12 h. The API concentration is commonly 25 mg/mL tylvalosin activity for poultry and swine dosing pumps. Acidifiers such as citric acid or acetic acid should not be added to the final drinking-water line because they can depress the pH below 5.0 and accelerate macrolide hydrolysis. The solution is packaged in amber HDPE containers with a light-protective overwrap; photolytic degradation is controlled by storage at 25 °C or below. Microbial limits are verified by Ph. Eur. 2.6.13, and content uniformity of the bulk solution is checked by HPLC after 24 h and 48 h to establish a use window. The terminal product is an oral solution for poultry and swine where feed medication is not feasible; published data for this specific configuration indicates that the 24 h window is the limiting operational boundary rather than chemical potency alone, because microbial growth in the waterline is the first observed failure mode in warm barn environments.

Oral top-dressing powders differ from feed premix in that the carrier is water-soluble lactose rather than corn cob meal, and the product is applied to a small quantity of feed immediately before administration rather than incorporated in a feed mill. The API is first passed through a 0.3 mm screen and pre-blended with lactose monohydrate at a ratio of 1:9 API-to-carrier in a 50 L drum blender at 15 rpm for 20 min. The blend is then mixed with a flavor-masked granule fraction containing maize starch and sucrose at 10% w/w of the final powder to improve intake in pigs. Residual moisture is controlled below 3.0% w/w by Ph. Eur. 2.2.32 because the powder is often opened and used under humid barn conditions; sachets with desiccant are specified for farm packaging. The terminal product is a top-dressing powder for individual or small-group treatment in swine breeding stock and weaners where automated water medication is not installed. The powder is administered at the dose approved for the target indication on a small amount of feed and is not intended for long-term storage after mixing. Uniformity of mass is controlled by Ph. Eur. 2.9.5, and the product is released by HPLC assay with UV detection at 280 nm after reconstitution in a pH 6.0 phosphate buffer.